---
title: "The chemical pharmaceutical sector fluctuated and rose, with BIOCAUSE HEILEN PHARMA up over 10%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/240482624.md"
description: "The chemical pharmaceutical sector fluctuated and rose, with BIOCAUSE HEILEN PHARMA up over 10%, Xinhua Pharm hitting the daily limit, and Jinshi Yayao, Haichuang Pharmaceutical, and Duorui Pharmaceutical following suit"
datetime: "2025-05-16T01:53:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/240482624.md)
  - [en](https://longbridge.com/en/news/240482624.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/240482624.md)
generator: "portal-rs"
---

# The chemical pharmaceutical sector fluctuated and rose, with BIOCAUSE HEILEN PHARMA up over 10%

The chemical pharmaceutical sector fluctuated and rose, with BIOCAUSE HEILEN PHARMA up over 10%, Xinhua Pharm hitting the daily limit, and Jinshi Yayao, Haichuang Pharmaceutical, and Duorui Pharmaceutical following suit

### Related Stocks

- [000756.CN](https://longbridge.com/en/quote/000756.CN.md)
- [00719.HK](https://longbridge.com/en/quote/00719.HK.md)
- [301211.CN](https://longbridge.com/en/quote/301211.CN.md)
- [300434.CN](https://longbridge.com/en/quote/300434.CN.md)
- [301075.CN](https://longbridge.com/en/quote/301075.CN.md)

## Related News & Research

- [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md)
- [OncoZenge registers 772,797 shares in directed issue after SEK 5 million payment from Sichuan Yangtian](https://longbridge.com/en/news/296607308.md)
- [CSPC Innovation Pharmaceutical: Biopharma licensing and product launches drove record revenue and profit growth](https://longbridge.com/en/news/296129143.md)
- [SandboxAQ introduces AQPotency for virtual drug screening](https://longbridge.com/en/news/296467103.md)
- [FONDIA: Profitability improved sharply in H1 2026, driven by growth in Finland and the Baltics](https://longbridge.com/en/news/296439068.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**